OncLive TV

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses recent advancements made in the field of triple-negative breast cancer.

Erika P. Hamilton, MD, discusses the complex treatment algorithm for HER2-positive breast cancer.

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in ​relapsed/refractory multiple myeloma. 

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in ​uterine and soft tissue leiomyosarcoma. 

Rutika J. Mehta, MD, MPH, discusses the ​current treatment paradigm in HER2-positive gastric cancer. 

Kartik Konduri, MD, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer.

Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.

Christian U. Blank, MD, PhD, discusses the OpACIN and OPACIN-neo trials examining ipilimumab plus nivolumab in stage III macroscopic melanoma. 

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.

Naiyer A. Rizvi, MD, discusses the utility of fam-trastuzumab deruxtecan-nxki  in non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.

Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.

Kamran A. Ahmed, MD, discusses the impact of neratinib on patients with central nervous system metastases and HER2-positive breast cancer.

Ulka N. Vaishampayan, MBBS, FAB, discusses the need to develop novel therapies for patients with metastatic renal cell carcinoma.

Caron Jacobson, MD, discusses the high-risk patient population within relapsed/refractory indolent non-Hodgkin lymphoma included in the phase 2 ZUMA-5 study.

Robert J. Motzer, MD, discusses the results of the phase 3 TIVO-3 trial with tivozanib versus sorafenib in patients with advanced renal cell carcinoma.

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.